RS61742B1 - Imunomodulatori za pet-snimanje - Google Patents

Imunomodulatori za pet-snimanje

Info

Publication number
RS61742B1
RS61742B1 RS20210499A RSP20210499A RS61742B1 RS 61742 B1 RS61742 B1 RS 61742B1 RS 20210499 A RS20210499 A RS 20210499A RS P20210499 A RSP20210499 A RS P20210499A RS 61742 B1 RS61742 B1 RS 61742B1
Authority
RS
Serbia
Prior art keywords
compound
subject
ethoxy
tissues
disease
Prior art date
Application number
RS20210499A
Other languages
English (en)
Serbian (sr)
Inventor
David J Donnelly
Kenneth M Boy
Yunhui Zhang
Joonyoung Kim
Adrienne Pena
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of RS61742B1 publication Critical patent/RS61742B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20210499A 2016-05-19 2017-05-17 Imunomodulatori za pet-snimanje RS61742B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators
EP17728696.0A EP3458111B1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
RS61742B1 true RS61742B1 (sr) 2021-05-31

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210499A RS61742B1 (sr) 2016-05-19 2017-05-17 Imunomodulatori za pet-snimanje

Country Status (25)

Country Link
US (2) US11103605B2 (https=)
EP (2) EP3458111B1 (https=)
JP (1) JP6953444B2 (https=)
KR (1) KR102378288B1 (https=)
CN (1) CN109414514B (https=)
AU (1) AU2017268291B2 (https=)
BR (1) BR112018073642A2 (https=)
CA (1) CA3024844A1 (https=)
CY (1) CY1124241T1 (https=)
DK (1) DK3458111T3 (https=)
EA (1) EA038019B1 (https=)
ES (1) ES2864091T3 (https=)
HR (1) HRP20210644T8 (https=)
HU (1) HUE054306T2 (https=)
IL (1) IL262962B (https=)
LT (1) LT3458111T (https=)
MA (1) MA53402A (https=)
MX (1) MX2018014028A (https=)
PL (1) PL3458111T3 (https=)
PT (1) PT3458111T (https=)
RS (1) RS61742B1 (https=)
SG (1) SG11201810177VA (https=)
SI (1) SI3458111T1 (https=)
SM (1) SMT202100238T1 (https=)
WO (1) WO2017201111A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
KR20240023665A (ko) * 2016-12-23 2024-02-22 더 존스 홉킨스 유니버시티 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
EP4087857B1 (en) 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
KR20220155332A (ko) * 2020-03-16 2022-11-22 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
KR20250117435A (ko) * 2022-12-12 2025-08-04 머크 샤프 앤드 돔 엘엘씨 그랜자임 b의 pet 영상화제로서의 시클릭 펩티드

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP0954340B1 (en) 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
EP0975374B1 (en) 1996-07-12 2007-12-05 Immunomedics, Inc. Radiometal-binding peptide analogues
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US6187284B1 (en) 1997-09-03 2001-02-13 Immunomedics, Inc. Fluorination of proteins and peptides for F-18 positron emission tomography
JP5605602B2 (ja) 2007-03-26 2014-10-15 国立大学法人 東京大学 環状ペプチド化合物の合成方法
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
EP2647720B1 (en) 2010-12-03 2019-06-19 The University of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
HRP20181271T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Ciklički peptidomimetički spojevi kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
CA2969067A1 (en) * 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂

Also Published As

Publication number Publication date
PT3458111T (pt) 2021-04-09
IL262962A (en) 2018-12-31
EA038019B1 (ru) 2021-06-23
AU2017268291B2 (en) 2022-09-29
JP2019520328A (ja) 2019-07-18
DK3458111T3 (da) 2021-04-26
MA53402A (fr) 2021-06-02
EA201892635A1 (ru) 2019-04-30
US20190117801A1 (en) 2019-04-25
EP3827849A1 (en) 2021-06-02
SMT202100238T1 (it) 2021-05-07
CA3024844A1 (en) 2017-11-23
PL3458111T3 (pl) 2021-06-28
KR20190009330A (ko) 2019-01-28
SG11201810177VA (en) 2018-12-28
IL262962B (en) 2020-04-30
HRP20210644T1 (hr) 2021-05-28
US11103605B2 (en) 2021-08-31
US20210386876A1 (en) 2021-12-16
WO2017201111A1 (en) 2017-11-23
HUE054306T2 (hu) 2021-08-30
ES2864091T3 (es) 2021-10-13
EP3458111B1 (en) 2021-03-03
EP3458111A1 (en) 2019-03-27
MX2018014028A (es) 2019-04-04
BR112018073642A2 (pt) 2019-02-26
AU2017268291A1 (en) 2019-01-17
JP6953444B2 (ja) 2021-10-27
CY1124241T1 (el) 2022-07-22
HRP20210644T8 (hr) 2021-06-25
CN109414514B (zh) 2022-03-11
SI3458111T1 (sl) 2021-07-30
LT3458111T (lt) 2021-05-25
KR102378288B1 (ko) 2022-03-23
CN109414514A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
US20210386876A1 (en) Pet-imaging immunomodulators
US20220202966A1 (en) Positron emitting radionuclide labeled peptides for human upar pet imaging
EP3223866B1 (en) Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
EP4537851A1 (en) Trifunctional compound and use thereof
US20160303258A1 (en) Compounds and compositions for imaging gcc-expressing cells
CN115286693B (zh) 针对癌胚抗原相关细胞黏附分子ceacam6的肿瘤靶向肽及其应用
Zhu et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
Lindeman et al. FAP radioligand linker optimization improves tumor dose and tumor-to-healthy organ ratios in 4T1 syngeneic model
Lamba et al. Synthetic 18 F labeled biomolecules that are selective and promising for PET imaging: major advances and applications
Liu et al. Development of an albumin-based PSMA probe with prolonged half-life
Oum et al. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4
CN119775367B (zh) 一种靶向Nectin-4的双环肽核素配体、探针及其制备方法与应用
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
Zeglis et al. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
Sun et al. Synthesis and biological evaluation of 68Ga-DOTA-AngII as a radiotracer for PET/MR imaging of hepatocellular carcinoma
Verena Development of bispecific prostate-specific membrane antigen/fibroblast activation protein (PSMA/FAP)-targeting radiotracers for prostate cancer imaging
Pang et al. 68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
WO2026083399A1 (en) Conjugates and use of same for theranostics
CN114081969A (zh) 标记的小分子抗体、及其标记方法和应用
CN110551075A (zh) 放射性标记亚谷氨基酸类化合物及其在制备pet显像剂的应用
Montemagno et al. Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer. Author names and affiliations.
BR112017010414B1 (pt) Sondas baseadas em proteína radiomarcada com 18f e composições farmacêuticas